# Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

> **NCT00991029** · PHASE3 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 4881 (actual)

## Conditions studied

- Ischemic Attack, Transient

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00991029
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05-28
- **Primary completion:** 2018-04-09
- **Final completion:** 2018-04-09
- **Target enrollment:** 4881 (ACTUAL)
- **Why stopped:** The trial was halted by the DSMB.
- **Last updated:** 2018-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991029, "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00991029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*